A multiple dose, double-blind, double-dummy, 3 period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 microg given either in the morning or in the evening in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD).

Trial Profile

A multiple dose, double-blind, double-dummy, 3 period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 microg given either in the morning or in the evening in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2012

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jul 2011 New trial record
    • 10 May 2011 The trial status is completed in Germany and is discontinued in United Kingdom.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top